IC
Ikarian Capital Portfolio holdings
AUM
$302M
This Quarter Return
+11.95%
1 Year Return
+65.21%
3 Year Return
+441.33%
5 Year Return
+548.26%
10 Year Return
–
AUM
$366M
AUM Growth
+$366M
(+36%)
Cap. Flow
+$7.51M
Cap. Flow
% of AUM
2.05%
Top 10 Holdings %
Top 10 Hldgs %
50.42%
Holding
132
New
23
Increased
7
Reduced
12
Closed
26
Top Buys
| 1 |
argenx
ARGX
|
$26.5M |
| 2 |
SPDR S&P Homebuilders ETF
XHB
|
$19.1M |
| 3 |
Amylyx Pharmaceuticals
AMLX
|
$12.9M |
| 4 |
Sarepta Therapeutics
SRPT
|
$12.8M |
| 5 |
Annexon
ANNX
|
$12M |
Top Sells
| 1 |
Rocket Pharmaceuticals
RCKT
|
$12.4M |
| 2 |
Akero Therapeutics
AKRO
|
$10.1M |
| 3 |
IMGN
Immunogen Inc
IMGN
|
$8.89M |
| 4 |
Vaxcyte
PCVX
|
$7.26M |
| 5 |
SLRN
ACELYRIN
SLRN
|
$6.92M |
Sector Composition
| 1 | Healthcare | 92.55% |
| 2 | Real Estate | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
CRISPR Therapeutics
CRSP
$4.82B
| $4.42M | 0.41% |
70,546
+40,000
| +131% | +$2.5M |
|
27
Dyne Therapeutics
DYN
$1.92B
| $3.8M | 0.36% |
+285,900
| New | +$3.8M |
|
|
ITOS
28
DELISTED
iTeos Therapeutics
ITOS
| $3.79M | 0.36% |
346,471
| – | – |
|
29
Abeona Therapeutics
ABEO
$356M
| $3.01M | 0.28% |
+600,000
| New | +$3.01M |
|
30
Edgewise Therapeutics
EWTX
$1.54B
| $2.95M | 0.28% |
+270,000
| New | +$2.95M |
|
31
Astria Therapeutics
ATXS
$394M
| $2.88M | 0.27% |
374,807
| – | – |
|
32
Larimar Therapeutics
LRMR
$337M
| $2.74M | 0.26% |
602,868
-80,000
| -12% | -$364K |
|
|
IMGN
33
DELISTED
Immunogen Inc
IMGN
| $2.67M | 0.25% |
90,162
-300,000
| -77% | -$8.89M |
|
34
Voyager Therapeutics
VYGR
$204M
| $2.58M | 0.24% |
305,857
| – | – |
|
35
Cytokinetics
CYTK
$5.98B
| $2.5M | 0.23% |
+30,000
| New | +$2.5M |
|
36
Moderna
MRNA
$9.36B
| $2.44M | 0.23% |
+24,546
| New | +$2.44M |
|
37
MindMed
MNMD
$689M
| $2.2M | 0.21% |
+600,000
| New | +$2.2M |
|
38
Apellis Pharmaceuticals
APLS
$3.51B
| $2.06M | 0.19% |
+34,361
| New | +$2.06M |
|
39
AEON Biopharma
AEON
$9.43M
| $1.86M | 0.17% |
257,977
| – | – |
|
40
Nuvation Bio
NUVB
$1.08B
| $1.85M | 0.17% |
1,222,852
| – | – |
|
41
Roivant Sciences
ROIV
$8.6B
| $1.7M | 0.16% |
151,821
+150,000
| +8,237% | +$1.68M |
|
|
AUTL
42
Autolus Therapeutics
AUTL
$383M
| $1.69M | 0.16% |
262,694
| – | – |
|
43
Black Diamond Therapeutics
BDTX
$164M
| $1.56M | 0.15% |
555,572
| – | – |
|
44
Kodiak Sciences
KOD
$453M
| $1.26M | 0.12% |
412,881
+100,000
| +32% | +$304K |
|
45
Acumen Pharmaceuticals
ABOS
$84.2M
| $1.21M | 0.11% |
315,265
| – | – |
|
46
Corbus Pharmaceuticals
CRBP
$121M
| $1.18M | 0.11% |
195,899
| – | – |
|
47
Coherus Oncology, Inc. Common Stock
CHRS
$146M
| $1.13M | 0.11% |
340,787
-525,000
| -61% | -$1.75M |
|
48
InflaRx
IFRX
$117M
| $1.12M | 0.11% |
688,604
| – | – |
|
49
Terns Pharmaceuticals
TERN
$651M
| $1.07M | 0.1% |
165,480
| – | – |
|
50
uniQure
QURE
$954M
| $1.07M | 0.1% |
157,365
| – | – |
|